Dr. Slaoui left GlaxoSmithKline in 2017 and has worked as a venture capitalist since. In his role as therapeutics czar, he will help coordinate the development of COVID-19 vaccines and treatments.
The position is part of a program the White House calls Operation Warp Speed, designed to drastically cut the time needed to develop a COVID-19 vaccine.
Dr. Slaoui also sits on the board of Moderna, a drugmaker developing a COVID-19 vaccine, Politico reported. His role as therapeutics czar will be split between HHS and the U.S. Defense Department.
Read the full article here.
More articles on pharmacy:
32 of 40 drugs deemed critical for COVID-19 in short supply
Gilead strikes deal to manufacture remdesivir for 127 countries
How Civica Rx has responded to drug shortages caused by COVID-19
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.